Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioVersys AG ( (CH:BIOV) ) just unveiled an update.
BioVersys reported substantial clinical and regulatory progress across its antibacterial pipeline in 2025, including initiation of the global registrational Phase 3 RIV-TARGET trial for BV100 in carbapenem-resistant Acinetobacter baumannii pneumonia and a planned Phase 2b RIV-CARE differentiation study supported by the ADVANCE-ID network. The company also advanced a Phase 1 study in China, secured Chinese patent protection for BV100, pushed alpibectir into Phase 2b pulmonary TB development with orphan designation in Europe, expanded into meningeal TB, and entered a lucrative global research and license option collaboration with Shionogi on its BV500 program.
Financially, BioVersys increased R&D investment to CHF 16.5 million as its candidates moved into later-stage trials, widening its 2025 net loss to CHF 21.8 million, but strengthened its balance sheet with CHF 76.7 million raised in a February IPO that lifted year-end cash to CHF 82.5 million and extended its funding runway into 2028. The combination of late-stage clinical momentum, strategic partnerships with GSK and Shionogi, and improving European policy support for novel antibiotics positions the company to play a more prominent role in the emerging market for treatments against multidrug-resistant infections, while providing shareholders with visibility toward a pivotal BV100 Phase 3 read-out expected by the end of 2027.
The most recent analyst rating on (CH:BIOV) stock is a Buy with a CHF40.00 price target. To see the full list of analyst forecasts on BioVersys AG stock, see the CH:BIOV Stock Forecast page.
More about BioVersys AG
BioVersys AG (SIX: BIOV) is a Basel-based, clinical-stage biopharmaceutical company developing novel antibacterial drugs targeting serious, life‑threatening infections caused by multidrug‑resistant bacteria. Its lead assets include BV100 for hospital-acquired and ventilator-associated bacterial pneumonia and alpibectir for tuberculosis, with an additional preclinical program BV500 in non-tuberculous mycobacteria under a collaboration with Shionogi.
Average Trading Volume: 3,416
Technical Sentiment Signal: Buy
Current Market Cap: CHF162.6M
For a thorough assessment of BIOV stock, go to TipRanks’ Stock Analysis page.